questionText: To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of dopamine agonist-related impulse control disorders and augmentation in people with restless legs syndrome and Parkinson’s disease on the economy, including effects on (a) employment and loss of earnings, (b) welfare and benefits claims and (c) mental health service use by patients and affected family members.
answerText: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
heading: Drugs: Side Effects